

Table 9.26
All Lymphoid Neoplasms With Detailed Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Males, 2004-2010

Site	All Ages		Ages 0-19	Ages 20-64	Ages 65+
	Count	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)
Lymphoid Neoplasm	93,448	67.7 (67.3 , 68.1)	88.3 (87.3 , 89.2)	73.8 (73.3 , 74.3)	57.1 (56.3 , 57.9)
1 Hodgkin Lymphoma	8,123	84.4 (83.4 , 85.3)	96.8 (95.3 , 97.8)	87.7 (86.6 , 88.6)	52.6 (48.2 , 56.8)
1(a) Classical Hodgkin lymphoma	7,632	83.7 (82.6 , 84.7)	96.5 (94.9 , 97.6)	87.1 (86.0 , 88.1)	51.2 (46.6 , 55.5)
1(a)1. Lymphocyte-rich/mixed cellularity/ lymphocyte-depleted	1,472	81.3 (78.6 , 83.6)	97.1 (92.0 , 98.9)	85.9 (83.2 , 88.2)	52.7 (43.7 , 60.9)
1(a)1.1 Lymphocyte-rich	296	87.8 (81.6 , 92.1)	100.0 (- , -)	91.3 (85.5 , 94.9)	60.0 (36.3 , 77.3)
1(a)1.2 Mixed cellularity	1,064	81.7 (78.7 , 84.4)	95.7 (88.5 , 98.4)	85.9 (82.6 , 88.5)	56.3 (45.7 , 65.6)
1(a)1.3 Lymphocyte-depleted	112	56.4 (44.8 , 66.4)	- (- , -)	67.1 (53.4 , 77.6)	20.1 (4.2 , 44.5)
1(a)2. Nodular sclerosis	4,414	88.3 (87.0 , 89.4)	96.4 (94.4 , 97.7)	90.0 (88.7 , 91.2)	55.5 (47.7 , 62.6)
1(a)3. Classical Hodgkin lymphoma, NOS ^c	1,746	73.8 (71.2 , 76.2)	96.1 (89.0 , 98.7)	79.9 (77.0 , 82.4)	44.3 (37.5 , 50.9)
1(b) Nodular lymphocyte predominant Hodgkin Lymphoma	491	95.3 (91.9 , 97.3)	100.0 (- , -)	96.4 (92.7 , 98.2)	77.6 (53.3 , 90.3)
2 Non-Hodgkin lymphoma	82,956	66.5 (66.1 , 67.0)	86.3 (85.1 , 87.4)	72.1 (71.6 , 72.7)	57.8 (57.0 , 58.5)
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	45	69.6 (49.6 , 82.9)	- (- , -)	65.6 (44.7 , 80.2)	- (- , -)
4 Lymphoid neoplasm, NOS ^c	2,324	49.4 (46.7 , 52.0)	82.9 (65.8 , 91.9)	59.0 (55.4 , 62.3)	39.7 (35.8 , 43.5)

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified.

- Statistic not displayed due to less than 25 cases.